Effect of Soluble ICAM-1 on Sjögren's Syndrome in Mice
Author Information
Author(s): Roescher Nienke, Vosters Jelle L., Yin Hongen, Illei Gabor G., Tak Paul P., Chiorini John A.
Primary Institution: Academic Medical Center, University of Amsterdam
Hypothesis
The timing of ICAM-1 interference may affect the outcome of Sjögren's syndrome treatment.
Conclusion
Early treatment with soluble ICAM-1 reduced inflammation in the salivary glands, while late treatment increased certain immune cell types.
Supporting Evidence
- Early treatment with ICAM-1/Fc resulted in decreased inflammatory foci in salivary glands.
- Late treatment did not reduce inflammation but increased CD4+ and CD8+ T cells.
- Immunoglobulin levels varied significantly based on the timing of treatment.
Takeaway
This study looked at how a treatment called soluble ICAM-1 affects mice with a disease similar to Sjögren's syndrome, finding that when given early, it helps reduce inflammation.
Methodology
NOD mice were treated with a gene therapy vector expressing soluble ICAM-1, and inflammation was assessed by focus score and immunohistochemistry.
Limitations
The study was conducted in mice, which may not fully replicate human disease.
Participant Demographics
Female NOD mice were used in the study.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website